Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04204941
Title Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Epizyme, Inc.
Indications

epithelioid sarcoma

sarcoma

Therapies

Doxorubicin

Doxorubicin + Tazemetostat

Age Groups: senior | adult
Covered Countries USA | CAN


No variant requirements are available.